Author: Donald Light
Publisher: Columbia University Press
ISBN: 0231146922
Category : Business & Economics
Languages : en
Pages : 179
Book Description
Few people realize that prescription drugs have become a leading cause of death, disease, and disability. Adverse reactions to widely used drugs, such as psychotropics and birth control pills, as well as biologicals, result in FDA warnings against adverse reactions. The Risks of Prescription Drugs describes how most drugs approved by the FDA are under-tested for adverse drug reactions, yet offer few new benefits. Drugs cause more than 2.2 million hospitalizations and 110,000 hospital-based deaths a year. Serious drug reactions at home or in nursing homes would significantly raise the total. Women, older people, and people with disabilities are least used in clinical trials and most affected. Health policy experts Donald Light, Howard Brody, Peter Conrad, Allan Horwitz, and Cheryl Stults describe how current regulations reward drug companies to expand clinical risks and create new diseases so millions of patients are exposed to unnecessary risks, especially women and the elderly. They reward developing marginally better drugs rather than discovering breakthrough, life-saving drugs. The Risks of Prescription Drugs tackles critical questions about the pharmaceutical industry and the privatization of risk. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the private sector and markets a greater role and reducing public oversight? This volume considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals. Chapters cover risks of statins for high cholesterol, SSRI drugs for depression and anxiety, and hormone replacement therapy for menopause. A final chapter outlines six changes to make drugs safer and more effective. Suitable for courses on health and aging, gender, disability, and minority studies, this book identifies the Risk Proliferation Syndrome that maximizes the number of people exposed to these risks. Additional Columbia / SSRC books on the privatization of risk and its implications for Americans: Bailouts: Public Money, Private ProfitEdited by Robert E. Wright Disaster and the Politics of InterventionEdited by Andrew Lakoff Health at Risk: America's Ailing Health System-and How to Heal ItEdited by Jacob S. Hacker Laid Off, Laid Low: Political and Economic Consequences of Employment InsecurityEdited by Katherine S. Newman Pensions, Social Security, and the Privatization of RiskEdited by Mitchell A. Orenstein
The Risks of Prescription Drugs
Author: Donald Light
Publisher: Columbia University Press
ISBN: 0231146922
Category : Business & Economics
Languages : en
Pages : 179
Book Description
Few people realize that prescription drugs have become a leading cause of death, disease, and disability. Adverse reactions to widely used drugs, such as psychotropics and birth control pills, as well as biologicals, result in FDA warnings against adverse reactions. The Risks of Prescription Drugs describes how most drugs approved by the FDA are under-tested for adverse drug reactions, yet offer few new benefits. Drugs cause more than 2.2 million hospitalizations and 110,000 hospital-based deaths a year. Serious drug reactions at home or in nursing homes would significantly raise the total. Women, older people, and people with disabilities are least used in clinical trials and most affected. Health policy experts Donald Light, Howard Brody, Peter Conrad, Allan Horwitz, and Cheryl Stults describe how current regulations reward drug companies to expand clinical risks and create new diseases so millions of patients are exposed to unnecessary risks, especially women and the elderly. They reward developing marginally better drugs rather than discovering breakthrough, life-saving drugs. The Risks of Prescription Drugs tackles critical questions about the pharmaceutical industry and the privatization of risk. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the private sector and markets a greater role and reducing public oversight? This volume considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals. Chapters cover risks of statins for high cholesterol, SSRI drugs for depression and anxiety, and hormone replacement therapy for menopause. A final chapter outlines six changes to make drugs safer and more effective. Suitable for courses on health and aging, gender, disability, and minority studies, this book identifies the Risk Proliferation Syndrome that maximizes the number of people exposed to these risks. Additional Columbia / SSRC books on the privatization of risk and its implications for Americans: Bailouts: Public Money, Private ProfitEdited by Robert E. Wright Disaster and the Politics of InterventionEdited by Andrew Lakoff Health at Risk: America's Ailing Health System-and How to Heal ItEdited by Jacob S. Hacker Laid Off, Laid Low: Political and Economic Consequences of Employment InsecurityEdited by Katherine S. Newman Pensions, Social Security, and the Privatization of RiskEdited by Mitchell A. Orenstein
Publisher: Columbia University Press
ISBN: 0231146922
Category : Business & Economics
Languages : en
Pages : 179
Book Description
Few people realize that prescription drugs have become a leading cause of death, disease, and disability. Adverse reactions to widely used drugs, such as psychotropics and birth control pills, as well as biologicals, result in FDA warnings against adverse reactions. The Risks of Prescription Drugs describes how most drugs approved by the FDA are under-tested for adverse drug reactions, yet offer few new benefits. Drugs cause more than 2.2 million hospitalizations and 110,000 hospital-based deaths a year. Serious drug reactions at home or in nursing homes would significantly raise the total. Women, older people, and people with disabilities are least used in clinical trials and most affected. Health policy experts Donald Light, Howard Brody, Peter Conrad, Allan Horwitz, and Cheryl Stults describe how current regulations reward drug companies to expand clinical risks and create new diseases so millions of patients are exposed to unnecessary risks, especially women and the elderly. They reward developing marginally better drugs rather than discovering breakthrough, life-saving drugs. The Risks of Prescription Drugs tackles critical questions about the pharmaceutical industry and the privatization of risk. To what extent does the FDA protect the public from serious side effects and disasters? What is the effect of giving the private sector and markets a greater role and reducing public oversight? This volume considers whether current rules and incentives put patients' health at greater risk, the effect of the expansion of disease categories, the industry's justification of high U.S. prices, and the underlying shifts in the burden of risk borne by individuals in the world of pharmaceuticals. Chapters cover risks of statins for high cholesterol, SSRI drugs for depression and anxiety, and hormone replacement therapy for menopause. A final chapter outlines six changes to make drugs safer and more effective. Suitable for courses on health and aging, gender, disability, and minority studies, this book identifies the Risk Proliferation Syndrome that maximizes the number of people exposed to these risks. Additional Columbia / SSRC books on the privatization of risk and its implications for Americans: Bailouts: Public Money, Private ProfitEdited by Robert E. Wright Disaster and the Politics of InterventionEdited by Andrew Lakoff Health at Risk: America's Ailing Health System-and How to Heal ItEdited by Jacob S. Hacker Laid Off, Laid Low: Political and Economic Consequences of Employment InsecurityEdited by Katherine S. Newman Pensions, Social Security, and the Privatization of RiskEdited by Mitchell A. Orenstein
A Risky Prescription
Author: Sandy Stiefer
Publisher: Lerner Publications
ISBN: 9780822533047
Category : Juvenile Nonfiction
Languages : en
Pages : 100
Book Description
Discusses athletes and sports in today's society, focusing on mental and physical health aspects, including the use of drugs, the stress placed on professional athletes, and the pressure to win at any cost.
Publisher: Lerner Publications
ISBN: 9780822533047
Category : Juvenile Nonfiction
Languages : en
Pages : 100
Book Description
Discusses athletes and sports in today's society, focusing on mental and physical health aspects, including the use of drugs, the stress placed on professional athletes, and the pressure to win at any cost.
Pain Management and the Opioid Epidemic
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309459575
Category : Medical
Languages : en
Pages : 483
Book Description
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Publisher: National Academies Press
ISBN: 0309459575
Category : Medical
Languages : en
Pages : 483
Book Description
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309672104
Category : Medical
Languages : en
Pages : 427
Book Description
Among the many who serve in the United States Armed Forces and who are deployed to distant locations around the world, myriad health threats are encountered. In addition to those associated with the disruption of their home life and potential for combat, they may face distinctive disease threats that are specific to the locations to which they are deployed. U.S. forces have been deployed many times over the years to areas in which malaria is endemic, including in parts of Afghanistan and Iraq. Department of Defense (DoD) policy requires that antimalarial drugs be issued and regimens adhered to for deployments to malaria-endemic areas. Policies directing which should be used as first and as second-line agents have evolved over time based on new data regarding adverse events or precautions for specific underlying health conditions, areas of deployment, and other operational factors At the request of the Veterans Administration, Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis assesses the scientific evidence regarding the potential for long-term health effects resulting from the use of antimalarial drugs that were approved by FDA or used by U.S. service members for malaria prophylaxis, with a focus on mefloquine, tafenoquine, and other antimalarial drugs that have been used by DoD in the past 25 years. This report offers conclusions based on available evidence regarding associations of persistent or latent adverse events.
Publisher: National Academies Press
ISBN: 0309672104
Category : Medical
Languages : en
Pages : 427
Book Description
Among the many who serve in the United States Armed Forces and who are deployed to distant locations around the world, myriad health threats are encountered. In addition to those associated with the disruption of their home life and potential for combat, they may face distinctive disease threats that are specific to the locations to which they are deployed. U.S. forces have been deployed many times over the years to areas in which malaria is endemic, including in parts of Afghanistan and Iraq. Department of Defense (DoD) policy requires that antimalarial drugs be issued and regimens adhered to for deployments to malaria-endemic areas. Policies directing which should be used as first and as second-line agents have evolved over time based on new data regarding adverse events or precautions for specific underlying health conditions, areas of deployment, and other operational factors At the request of the Veterans Administration, Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis assesses the scientific evidence regarding the potential for long-term health effects resulting from the use of antimalarial drugs that were approved by FDA or used by U.S. service members for malaria prophylaxis, with a focus on mefloquine, tafenoquine, and other antimalarial drugs that have been used by DoD in the past 25 years. This report offers conclusions based on available evidence regarding associations of persistent or latent adverse events.
A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309212804
Category : Medical
Languages : en
Pages : 206
Book Description
With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every day. Often the decisions must be made quickly and on the basis of incomplete information. FDA recognized that collecting and evaluating information on the risks posed by the regulated products in a systematic manner would aid in its decision-making process. Consequently, FDA and the Department of Health and Human Services (DHHS) asked the National Research Council (NRC) to develop a conceptual model that could evaluate products or product categories that FDA regulates and provide information on the potential health consequences associated with them. A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration describes the proposed risk-characterization framework that can be used to evaluate, compare, and communicate the public-health consequences of decisions concerning a wide variety of products. The framework presented in this report is intended to complement other risk-based approaches that are in use and under development at FDA, not replace them. It provides a common language for describing potential public-health consequences of decisions, is designed to have wide applicability among all FDA centers, and draws extensively on the well-vetted risk literature to define the relevant health dimensions for decision-making at the FDA. The report illustrates the use of that framework with several case studies, and provides conclusions and recommendations.
Publisher: National Academies Press
ISBN: 0309212804
Category : Medical
Languages : en
Pages : 206
Book Description
With the responsibility to ensure the safety of food, drugs, and other products, the U.S. Food and Drug Administration (FDA) faces decisions that may have public-health consequences every day. Often the decisions must be made quickly and on the basis of incomplete information. FDA recognized that collecting and evaluating information on the risks posed by the regulated products in a systematic manner would aid in its decision-making process. Consequently, FDA and the Department of Health and Human Services (DHHS) asked the National Research Council (NRC) to develop a conceptual model that could evaluate products or product categories that FDA regulates and provide information on the potential health consequences associated with them. A Risk-Characterization Framework for Decision-Making at the Food and Drug Administration describes the proposed risk-characterization framework that can be used to evaluate, compare, and communicate the public-health consequences of decisions concerning a wide variety of products. The framework presented in this report is intended to complement other risk-based approaches that are in use and under development at FDA, not replace them. It provides a common language for describing potential public-health consequences of decisions, is designed to have wide applicability among all FDA centers, and draws extensively on the well-vetted risk literature to define the relevant health dimensions for decision-making at the FDA. The report illustrates the use of that framework with several case studies, and provides conclusions and recommendations.
Prescription for Disaster
Author: Thomas J. Moore
Publisher:
ISBN:
Category : Family & Relationships
Languages : en
Pages : 280
Book Description
This hard-hitting expose does for prescription drugs what "Silent Spring" did for pesticides, revealing the hidden dangers of the most commonly prescribed medications--and what the consumer can do to minimize the risks of serious side effects.
Publisher:
ISBN:
Category : Family & Relationships
Languages : en
Pages : 280
Book Description
This hard-hitting expose does for prescription drugs what "Silent Spring" did for pesticides, revealing the hidden dangers of the most commonly prescribed medications--and what the consumer can do to minimize the risks of serious side effects.
Complete Guide to Prescription and Nonprescription Drugs 2013
Author: H. Winter Griffith
Publisher: Penguin
ISBN: 110161241X
Category : Health & Fitness
Languages : en
Pages : 2293
Book Description
This newly revised, expanded 2013 edition of the bestselling drug reference book features more than 6,000 brand names and 1,000 generic names plus: revised information on new FDA changes easy-to-use chart format for quick access to data information on dangerous interactions and side effects warnings and vital data for safe use comprehensive coverage of lifestyle drugs -- skin aging, obesity, sexual dysfunction, and more
Publisher: Penguin
ISBN: 110161241X
Category : Health & Fitness
Languages : en
Pages : 2293
Book Description
This newly revised, expanded 2013 edition of the bestselling drug reference book features more than 6,000 brand names and 1,000 generic names plus: revised information on new FDA changes easy-to-use chart format for quick access to data information on dangerous interactions and side effects warnings and vital data for safe use comprehensive coverage of lifestyle drugs -- skin aging, obesity, sexual dysfunction, and more
Complete Guide to Prescription & Nonprescription Drugs 2011
Author: H. Winter Griffith
Publisher: Penguin
ISBN: 110144486X
Category : Health & Fitness
Languages : en
Pages : 2570
Book Description
The revised and updated 2011 edition of the most accessible, comprehensive and affordable guide to prescription and nonprescription drugs. The classic guide to all major prescription and nonprescription drugs, featuring revised, up-to date FDA information and an A-Z list of medical conditions and their commonly used drugs for easy reference. It includes coverage of dosage and length of time before the drug takes effect, side effects, special precautions, interactions with other food and drugs, standards for use by different age groups, and much more. It also features a generic and brand name directory, a comprehensive glossary, and complete index by generic, brand, and class name.
Publisher: Penguin
ISBN: 110144486X
Category : Health & Fitness
Languages : en
Pages : 2570
Book Description
The revised and updated 2011 edition of the most accessible, comprehensive and affordable guide to prescription and nonprescription drugs. The classic guide to all major prescription and nonprescription drugs, featuring revised, up-to date FDA information and an A-Z list of medical conditions and their commonly used drugs for easy reference. It includes coverage of dosage and length of time before the drug takes effect, side effects, special precautions, interactions with other food and drugs, standards for use by different age groups, and much more. It also features a generic and brand name directory, a comprehensive glossary, and complete index by generic, brand, and class name.
Complete Guide to Prescription and Nonprescription Drugs 2015
Author: H. Winter Griffith
Publisher: Penguin
ISBN: 0698165519
Category : Health & Fitness
Languages : en
Pages : 1122
Book Description
The 2015 edition of the most accessible, comprehensive and affordable guide to prescription and nonprescription drugs. The classic guide to all major prescription and nonprescription drugs, featuring revised, up to date FDA information and an A-Z list of illnesses for easy reference. Includes coverage of dosage and length of time before drug takes effect; side effects, special precautions; interactions with other food and drugs; standards for use by different age groups, and more
Publisher: Penguin
ISBN: 0698165519
Category : Health & Fitness
Languages : en
Pages : 1122
Book Description
The 2015 edition of the most accessible, comprehensive and affordable guide to prescription and nonprescription drugs. The classic guide to all major prescription and nonprescription drugs, featuring revised, up to date FDA information and an A-Z list of illnesses for easy reference. Includes coverage of dosage and length of time before drug takes effect; side effects, special precautions; interactions with other food and drugs; standards for use by different age groups, and more
The Feeling of Risk
Author: Paul Slovic
Publisher: Routledge
ISBN: 1136530479
Category : Business & Economics
Languages : en
Pages : 457
Book Description
The Feeling of Risk brings together the work of Paul Slovic, one of the world's leading analysts of risk, to describe the extension of risk perception research into the first decade of this new century. In this collection of important works, Paul Slovic explores the conception of 'risk as feelings' and examines the interaction of feeling and cognition in the perception of risk. He also examines the elements of knowledge, cognitive skill, and communication necessary for good decisions in the face of risk. The first section of the book looks at the difficulty of understanding risk without an emotional component, for example that disaster statistics lack emotion and thus fail to convey the true meaning of disasters and fail to motivate proper action to prevent them. The book also highlights other important perspectives on risk arising from cultural worldviews and concerns about specific hazards pertaining to blood transfusion, biotechnology, prescription drugs, smoking, terrorism, and nanotechnology. Following on from The Perception of Risk (2000), this book presents some of the most significant research on risk perception in recent years, providing essential lessons for all those involved in risk perception and communication.
Publisher: Routledge
ISBN: 1136530479
Category : Business & Economics
Languages : en
Pages : 457
Book Description
The Feeling of Risk brings together the work of Paul Slovic, one of the world's leading analysts of risk, to describe the extension of risk perception research into the first decade of this new century. In this collection of important works, Paul Slovic explores the conception of 'risk as feelings' and examines the interaction of feeling and cognition in the perception of risk. He also examines the elements of knowledge, cognitive skill, and communication necessary for good decisions in the face of risk. The first section of the book looks at the difficulty of understanding risk without an emotional component, for example that disaster statistics lack emotion and thus fail to convey the true meaning of disasters and fail to motivate proper action to prevent them. The book also highlights other important perspectives on risk arising from cultural worldviews and concerns about specific hazards pertaining to blood transfusion, biotechnology, prescription drugs, smoking, terrorism, and nanotechnology. Following on from The Perception of Risk (2000), this book presents some of the most significant research on risk perception in recent years, providing essential lessons for all those involved in risk perception and communication.